×
About 2,123 results

ALLMedicine™ Autoimmune Hemolytic Anemia Center

Research & Reviews  1,041 results

Autoimmune hemolytic anemia complicated by parvovirus infection.
https://doi.org/10.1182/blood.2020009849
Blood Wachter F, Archer NM

Feb 25th, 2021 - Autoimmune hemolytic anemia complicated by parvovirus infection.|2021|Wachter F,Archer NM,|

How I treat warm autoimmune hemolytic anemia.
https://doi.org/10.1182/blood.2019003808
Blood Barcellini W, Fattizzo B

Jan 29th, 2021 - Warm autoimmune hemolytic anemia (wAIHA) is caused by increased erythrocyte destruction by IgG autoantibodies, with or without complement activation. Antibody-dependent cell-mediated cytotoxicity by macrophages/activated lymphocytes occurs in the ...

Features of serum complement C3 and C4 levels in autoimmune hemolytic anemia patients.
https://doi.org/10.1111/ijlh.13469
International Journal of Laboratory Hematology REFERENCES; Wang Z, Bo L et. al.

Jan 18th, 2021 - Abnormally activated complement system induces erythrolysis in a part of autoimmune hemolytic anemia (AIHA) patients. However, the alterations in serum complement levels in these patients are seldom reported. In this study, we aimed to evaluate th...

see more →

Guidelines  2 results

Apellis’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of Autoimmune Hemolytic Anemia
http://investors.apellis.com/news-releases/news-release-details/apellis-apl-2-receives-orphan-drug-designation-fda-treatment

Feb 4th, 2019 - Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases through inhibition of the complement system, today announced that its C3 complement ...

FDA grants orphan drug designation to APL-2 for autoimmune hemolytic anemia
https://www.healio.com/hematology-oncology/hematology/news/online/%7B2785cd04-4008-4105-91cc-e82f5573ee6f%7D/fda-grants-orphan-drug-designation-to-apl-2-for-autoimmune-hemolytic-anemia

Feb 4th, 2019 - The FDA granted orphan drug designation to the C3 complement inhibitor APL-2 for the treatment of autoimmune hemolytic anemia. Autoimmune hemolytic anemia refers to both cold agglutinin disease and warm autoimmune hemolytic anemia, which affect a ...

see more →

Clinicaltrials.gov  1,045 results

Autoimmune hemolytic anemia complicated by parvovirus infection.
https://doi.org/10.1182/blood.2020009849
Blood Wachter F, Archer NM

Feb 25th, 2021 - Autoimmune hemolytic anemia complicated by parvovirus infection.|2021|Wachter F,Archer NM,|

How I treat warm autoimmune hemolytic anemia.
https://doi.org/10.1182/blood.2019003808
Blood Barcellini W, Fattizzo B

Jan 29th, 2021 - Warm autoimmune hemolytic anemia (wAIHA) is caused by increased erythrocyte destruction by IgG autoantibodies, with or without complement activation. Antibody-dependent cell-mediated cytotoxicity by macrophages/activated lymphocytes occurs in the ...

Features of serum complement C3 and C4 levels in autoimmune hemolytic anemia patients.
https://doi.org/10.1111/ijlh.13469
International Journal of Laboratory Hematology REFERENCES; Wang Z, Bo L et. al.

Jan 18th, 2021 - Abnormally activated complement system induces erythrolysis in a part of autoimmune hemolytic anemia (AIHA) patients. However, the alterations in serum complement levels in these patients are seldom reported. In this study, we aimed to evaluate th...

see more →

News  35 results

Sutimlimab boosts hemoglobin, quality of life in cold agglutinin disease
https://www.mdedge.com/hematology-oncology/article/214191/anemia/sutimlimab-boosts-hemoglobin-quality-life-cold-agglutinin?channel=39313
Neil Osterweil

Dec 12th, 2019 - ORLANDO – An investigational selective inhibitor of the complement pathway, sutimlimab, induced rapid and sustained benefits in patients with cold agglutinin disease, a rare autoimmune hemolytic anemia with no currently approved effective therapie.

Autoimmune Hemolytic Anemia: Evaluation and Diagnosis
https://www.mdedge.com/hematology-oncology/article/210264/anemia/autoimmune-hemolytic-anemia-evaluation-and-diagnosis/page/0/3?channel=182

Oct 18th, 2019 - Transfusion Therapy Performing transfusions can be very difficult in patients with AIHA. 2 The presence of the autoantibody can interfere with typing of the blood and almost always interferes with the crossmatch, since this final step consists of m.

Autoimmune Hemolytic Anemia: Treatment of Common Types
https://www.mdedge.com/hematology-oncology/article/210272/anemia/autoimmune-hemolytic-anemia-treatment-common-types/page/0/4?channel=182

Oct 18th, 2019 - Drug-Induced Hemolytic Anemia AIHA caused by a drug reaction is rare, with a lower incidence than drug-related ITP. The rate of severe drug-related AIHA is estimated at 1:1,000,000, but less severe cases may be missed.

C3 inhibitor shows potential in PNH and AIHA
https://www.mdedge.com/hematology-oncology/article/199135/anemia/c3-inhibitor-shows-potential-pnh-and-aiha?channel=39313
Will Pass

Apr 18th, 2019 - GLASGOW – APL-2, a complement factor 3 (C3) inhibitor, may be a future treatment option for paroxysmal nocturnal hemoglobinuria (PNH) and autoimmune hemolytic anemia (AIHA), according to investigators from two separate studies. Will Pass/MDedge Ne.

Apellis’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of Autoimmune Hemolytic Anemia
http://investors.apellis.com/news-releases/news-release-details/apellis-apl-2-receives-orphan-drug-designation-fda-treatment

Feb 4th, 2019 - Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases through inhibition of the complement system, today announced that its C3 complement ...

see more →